Tech Company Financing Transactions
RAPT Therapeutics Funding Round
RAPT Therapeutics, operating out of San Francisco, secured $37 million from Celgene, GV and Kleiner Perkins Caufield & Byers.
Transaction Overview
Company Name
Announced On
6/19/2019
Transaction Type
Venture Equity
Amount
$37,000,000
Round
Series C
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
561 Eccles Ave.
San Francisco, CA 94080
USA
San Francisco, CA 94080
USA
Phone
Website
Email Address
Overview
We changed our name to RAPT Therapeutics (formerly FLX Bio) (Nasdaq: RAPT) to more accurately represent the company's unrelenting determination and passionate drive to leverage our expertise in immunology, small molecule drug discovery and computational biology to conquer cancer and allergic inflammatory diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Brian Wong
Chief Medical Officer
William Ho
Vice President
Dirk Brockstedt
Vice President
Paul Kassner
Vice President
David Wustrow
Browse more venture capital transactions:
Prev: 6/19/2019: AnyVision venture capital transaction
Next: 6/19/2019: Element Biosciences venture capital transaction
Share this article
Where The Data Comes From
We do our best to record every notable VC transaction. VC investment data records reported here are derived from a variety of public sources. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs